» Articles » PMID: 27012190

The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2016 Mar 26
PMID 27012190
Citations 453
Authors
Affiliations
Soon will be listed here.
Abstract

Since our proposal of a dualistic model of epithelial ovarian carcinogenesis more than a decade ago, a large number of molecular and histopathologic studies were published that have provided important insights into the origin and molecular pathogenesis of this disease. This has required that the original model be revised and expanded to incorporate these findings. The new model divides type I tumors into three groups: i) endometriosis-related tumors that include endometrioid, clear cell, and seromucinous carcinomas; ii) low-grade serous carcinomas; and iii) mucinous carcinomas and malignant Brenner tumors. As in the previous model, type II tumors are composed, for the most part, of high-grade serous carcinomas that can be further subdivided into morphologic and molecular subtypes. Type I tumors develop from benign extraovarian lesions that implant on the ovary and which can subsequently undergo malignant transformation, whereas many type II carcinomas develop from intraepithelial carcinomas in the fallopian tube and, as a result, disseminate as carcinomas that involve the ovary and extraovarian sites, which probably accounts for their clinically aggressive behavior. The new molecular genetic data, especially those derived from next-generation sequencing, further underline the heterogeneity of ovarian cancer and identify actionable mutations. The dualistic model highlights these differences between type I and type II tumors which, it can be argued, describe entirely different groups of diseases.

Citing Articles

Establishment of a Novel In Vitro and In Vivo Model to Understand Molecular Carcinogenesis of Endometriosis-Related Ovarian Neoplasms.

Sohel H, Kiyono T, Zahan U, Razia S, Ishikawa M, Yamashita H Int J Mol Sci. 2025; 26(5).

PMID: 40076621 PMC: 11901000. DOI: 10.3390/ijms26051995.


Circulating Tumour DNA for Ovarian Cancer Diagnosis and Treatment Monitoring: What Perspectives for Clinical Use?.

Asante D, Tierno D, Grassi G, Scaggiante B Int J Mol Sci. 2025; 26(5).

PMID: 40076521 PMC: 11900478. DOI: 10.3390/ijms26051889.


17β-Hydroxysteroid dehydrogenase type I and aromatase in ovarian cortical inclusion cysts.

Pedernera E, Morales-Vasquez F, Perez-Montiel D, Rendon E, Mena E, Diaz-Cueto L Endocr Connect. 2025; 14(4).

PMID: 40008686 PMC: 11906145. DOI: 10.1530/EC-24-0643.


Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.

Borella F, Carosso M, Chiparo M, Ferraioli D, Bertero L, Gallio N Pathogens. 2025; 14(2).

PMID: 40005517 PMC: 11858389. DOI: 10.3390/pathogens14020140.


Identification of AKNA Gene and Its Role for Genetic Susceptibility in Epithelial Ovarian Cancer.

Suryandari D, Miftahuzzakiyah M, Yunaini L, Kodariah R, Sukmawati D, Rustamadji P Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996799 PMC: 11854646. DOI: 10.3390/cimb47020078.


References
1.
Kobayashi Y, Kashima H, Wu R, Jung J, Kuan J, Gu J . Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. Clin Cancer Res. 2015; 21(20):4652-62. PMC: 4609247. DOI: 10.1158/1078-0432.CCR-14-3368. View

2.
Saegusa M, Hashimura M, Yoshida T, Okayasu I . beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer. 2001; 84(2):209-17. PMC: 2363713. DOI: 10.1054/bjoc.2000.1581. View

3.
Konecny G, Wang C, Hamidi H, Winterhoff B, Kalli K, Dering J . Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014; 106(10). PMC: 4271115. DOI: 10.1093/jnci/dju249. View

4.
George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A . Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res. 2013; 19(13):3474-84. DOI: 10.1158/1078-0432.CCR-13-0066. View

5.
Jones S, Wang T, Shih I, Mao T, Nakayama K, Roden R . Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010; 330(6001):228-31. PMC: 3076894. DOI: 10.1126/science.1196333. View